SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending following the announcement of a 10-year AI hosting agreement with Fluidstack, potentially worth billions, which includes Google backstopping a significant portion. The community is excited about this strategic shift from crypto mining to AI infrastructure, anticipating substantial revenue and increased stock value. Some traders believe that the deal is already baked in and that the stock will experience a "sell the news event" as a result.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas is trending amid reports that the U.S. government is considering taking an equity stake in the company, which is fueling speculation of increased government support and reduced dependence on foreign lithium sources. The community is actively discussing the potential for a short squeeze and comparing it to other government-backed ventures, while also weighing analyst downgrades and potential dilution. Some traders are looking at related stocks for similar potential moves.

Aventus Network

Aventus Network ($AVT.X) is gaining traction as traders highlight its strong chart setup and potential breakout, with community members pointing to real-world partnerships and Polkadot integration as possible catalysts. Bullish sentiment is fueled by its low market cap and limited supply, although some express concern about low volume and consistent gains. Recent updates from Aventus on LinkedIn, including news of a new advisor and the integration of their technology with Heathrow Airport and Vodafone, appear to be contributing to the increased interest.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to positive trial data showing significant slowing of Huntington's disease progression with its gene therapy, potentially paving the way for FDA approval. The community is buzzing about the therapy's efficacy and potential market impact, while also weighing concerns of dilution following the announcement of a public offering and insider selling. Bullish investors are focused on long-term potential in a growing biotech sector, while bears are skeptical of the recent surge and near-term dilution.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive Phase 2a trial results for its pancreatic cancer treatment, showing high overall survival rates. Despite the encouraging data, the stock's momentum is tempered by the announcement of a $175 million public offering and a $25 million private placement to Sanofi, leading to community debate about dilution and fair valuation. The community is actively discussing the potential for long-term growth versus short-term price suppression from the offering, as well as comparisons to other companies in the sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as community members discuss its valuation and potential for future growth within the quantum computing sector. Conversations include commentary around a recent photon conversion breakthrough, and whether the company can deliver on long-term promises. Short sellers and bullish investors are actively debating the stock's near-term direction and long-term potential.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid excitement around quantum computing, with community members discussing potential catalysts like government contracts and advancements in qubit technology. Some are pointing to a recent Air Force contract and comparing it to other high-flying stocks, while others express concern about the company's valuation and potential for a pullback. Overall, the conversation is focused on whether the stock's momentum can continue, given the speculative nature of the quantum computing sector.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending amid mixed sentiment, with some traders eyeing potential NASA contract news as a catalyst, while others point to technical patterns and short interest. The community is actively debating potential breakout levels and whether the stock can sustain recent gains, with some expressing frustration over its performance relative to other space sector stocks. Discussions also include the impact of overall market conditions and potential upcoming news.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss potential partnerships and the upcoming earnings report. The community is focused on a possible short squeeze, with some expressing strong bullish sentiment. There is also speculation about unusual ticker behavior on some platforms and what it could mean for the stock's future.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending amid speculation of a potential takeover, with community members citing a blog report about a strategic buyer possibly seeking a bridge loan for the acquisition. The community is actively discussing potential acquirers and deal structures, while also considering the company's fundamentals and upcoming catalysts. Some traders believe that this could present an opportunity for the company's value to be unlocked.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Best Momentum Stock to Buy for August 15th

ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Options Traders Betting on a Big Move in Harrow Stock?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Harrow Health, Inc reported a wider first-quarter loss on Thursday but reaffirmed its full-year revenue outlook, prompting a pickup in retail trading activity.The eyecare pharmaceutical firm posted a net loss of $17.8 million, or 38 cents per share, compared with a loss of $13.6 million, or 28 cents per share, a year earlier.&nbsp;Harrow shares closed at $23.59, down 4.07% on Thursday, and dropped further in after-hours trading, falling $2.49, or 10.56% to $21.10.Revenue rose 38% year-over-year to $47.8 million, driven by increased uptake of Vevye, a prescription ophthalmic drug for dry eye disease.&nbsp;Vevye recorded $21.5 million in sales during the quarter.The company cited strong early demand from its new ‘Vevye Access for All’ program, launched in mid-March, with prescription volumes at specialty pharmacy PhilRx more than quadrupling.“Our Vevye refill rate continues to be buoyant, with the average covered patient receiving nine refills,” CEO Mark L. Baum said in a statement.Harrow reaffirmed its 2025 revenue target of over $280 million, slightly below analysts’ average estimate of $283.2 million.&nbsp;The company said it expects continued commercial momentum from its Iheezo and Triesence products, along with contributions from pending pipeline accounts.Management also reiterated its focus on strategic acquisitions to augment its U.S. commercial platform, calling out opportunities to add “high-quality ophthalmic pharmaceutical assets.”Sentiment on Stocktwits was described as "extremely bullish," amid a 2,200% surge in 24-hour message volume.One user expressed strong enthusiasm for the stock, commenting that there was "never a bad price to buy HROW" and that no matter the outcome, it's always "good news."&nbsp;<stembedurl>https://stocktwits.com/dpen1000/message/614022779</stembedurl>Another user highlighted the potential for VEVYE’s continued growth, noting that if it maintains its 35% quarter-over-quarter increase, the product alone could contribute $150 million in revenue for 2025.<stembedurl>https://stocktwits.com/HROW200/message/614007884</stembedurl>The stock has declined over 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue

The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue target of over $280 million.

Equity

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Stock Index Futures Gain With All Eyes on Fed Rate Decision

March S&P 500 E-Mini futures (ESH25) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the Federal Reserve’s policy decision and Chair Jerome Powell’s comments.

S&P Futures Tread Water Ahead of FOMC Meeting and U.S. Economic Data

March S&P 500 E-Mini futures (ESH25) are trending up +0.04% this morning as investors await the start of the Federal Reserve’s two-day policy meeting and a fresh batch of U.S. economic data.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Current Price	$48.00
Prev Close	$48.85
Open	$48.50
Dividend Yield	0.00%
50-Day Moving Average	$37.69
Beta	1.03
Avg. Volume	656,401.24
PE Ratio	-164.64

52-Week High	$59.23
52-Week Low	$20.85
Market Capitalization	$1.81B
EPS (Annual)	-$0.4903
Price to Book	36.12
Revenue Per Employee	$522,549.74
Enterprise Value/EBITDA	N/A

HROW
Harrow Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HROW News

HROW Harrow Health Inc